ABSTRACT
Efforts to identify lupus-associated causal variants in the FAM167A/BLK locus on 8p21 are hampered by highly associated noncausal variants. In this report, we used a trans-population mapping and sequencing strategy to identify a common variant (rs922483) in the proximal BLK promoter and a tri-allelic variant (rs1382568) in the upstream alternative BLK promoter as putative causal variants for association with systemic lupus erythematosus. The risk allele (T) at rs922483 reduced proximal promoter activity and modulated alternative promoter usage. Allelic differences at rs1382568 resulted in altered promoter activity in B progenitor cell lines. Thus, our results demonstrated that both lupus-associated functional variants contribute to the autoimmune disease association by modulating transcription of BLK in B cells and thus potentially altering immune responses.
Subject(s)
Lupus Erythematosus, Systemic/genetics , Promoter Regions, Genetic , Transcription, Genetic , src-Family Kinases/genetics , Alleles , Chromosomes, Human, Pair 8 , Electrophoretic Mobility Shift Assay , Female , Genetic Predisposition to Disease , Haplotypes , Humans , Male , Polymorphism, Single NucleotideABSTRACT
A series of novel substituted-[(3R)-amino-2-(2,5-difluorophenyl)]tetrahydro-2H-pyran analogs have been prepared and evaluated as potent, selective and orally active DPP-4 inhibitors. These efforts lead to the discovery of a long acting DPP-4 inhibitor, omarigliptin (MK-3102), which recently completed phase III clinical development and has been approved in Japan.
Subject(s)
Amides/chemistry , Dipeptidyl-Peptidase IV Inhibitors/chemistry , Heterocyclic Compounds, 2-Ring/chemistry , Pyrans/chemistry , Sulfonamides/chemistry , Animals , Binding Sites , Dipeptidyl Peptidase 4/chemistry , Dipeptidyl Peptidase 4/metabolism , Dipeptidyl-Peptidase IV Inhibitors/chemical synthesis , Dipeptidyl-Peptidase IV Inhibitors/pharmacokinetics , Dogs , Half-Life , Heterocyclic Compounds, 2-Ring/chemical synthesis , Heterocyclic Compounds, 2-Ring/pharmacokinetics , Molecular Docking Simulation , Protein Structure, Tertiary , Pyrans/chemical synthesis , Pyrans/pharmacokinetics , Rats , Structure-Activity RelationshipABSTRACT
Using structure based drug design (SBDD), a novel class of potent coagulation Factor IXa (FIXa) inhibitors was designed and synthesized. High selectivity over FXa inhibition was achieved. Selected compounds demonstrated oral bioavailability in rat IV/PO pharmacokinetic (PK) studies. Finally, the pharmacodynamics (PD) of this class of molecules was evaluated in Thrombin Generation Assay (TGA) in Corn Trypsin Inhibitor (CTI) citrated human plasma and demonstrated characteristics of a FIXa inhibitor.
Subject(s)
Amines/pharmacology , Enzyme Inhibitors/pharmacology , Factor IXa/antagonists & inhibitors , Administration, Oral , Amines/chemical synthesis , Amines/chemistry , Animals , Biological Availability , Crystallography, X-Ray , Dose-Response Relationship, Drug , Drug Design , Enzyme Inhibitors/chemical synthesis , Enzyme Inhibitors/chemistry , Factor IXa/metabolism , Humans , Models, Molecular , Molecular Structure , Rats , Structure-Activity RelationshipABSTRACT
Systemic lupus erythematosus (SLE) is a complex autoimmune disease with a strong genetic predisposition, characterized by an upregulated type I interferon pathway. MicroRNAs are important regulators of immune homeostasis, and aberrant microRNA expression has been demonstrated in patients with autoimmune diseases. We recently identified miR-146a as a negative regulator of the interferon pathway and linked the abnormal activation of this pathway to the underexpression of miR-146a in SLE patients. To explore why the expression of miR-146a is reduced in SLE patients, we conducted short parallel sequencing of potentially regulatory regions of miR-146a and identified a novel genetic variant (rs57095329) in the promoter region exhibiting evidence for association with SLE that was replicated independently in 7,182 Asians (P(meta)â=â2.74×10(-8), odds ratioâ=â1.29 [1.18-1.40]). The risk-associated G allele was linked to reduced expression of miR-146a in the peripheral blood leukocytes of the controls. Combined functional assays showed that the risk-associated G allele reduced the protein-binding affinity and activity of the promoter compared with those of the promoter containing the protective A allele. Transcription factor Ets-1, encoded by the lupus-susceptibility gene ETS1, identified in recent genome-wide association studies, binds near this variant. The manipulation of Ets-1 levels strongly affected miR-146a promoter activity in vitro; and the knockdown of Ets-1, mimicking its reduced expression in SLE, directly impaired the induction of miR-146a. We also observed additive effects of the risk alleles of miR-146a and ETS1. Our data identified and confirmed an association between a functional promoter variant of miR-146a and SLE. This risk allele had decreased binding to transcription factor Ets-1, contributing to reduced levels of miR-146a in SLE patients.
Subject(s)
Gene Expression Regulation/genetics , Genetic Predisposition to Disease/genetics , Lupus Erythematosus, Systemic/genetics , Lupus Erythematosus, Systemic/metabolism , MicroRNAs/genetics , MicroRNAs/metabolism , Promoter Regions, Genetic/genetics , Alleles , Cell Line, Tumor , Genotype , HeLa Cells , Humans , Models, Biological , Nuclear Proteins/metabolism , Polymorphism, Single Nucleotide/genetics , Protein Binding/physiology , Proto-Oncogene Protein c-ets-1/genetics , Proto-Oncogene Protein c-ets-1/metabolism , Risk FactorsABSTRACT
Systemic lupus erythematosus (SLE), a complex polygenic autoimmune disease, is associated with increased complement activation. Variants of genes encoding complement regulator factor H (CFH) and five CFH-related proteins (CFHR1-CFHR5) within the chromosome 1q32 locus linked to SLE, have been associated with multiple human diseases and may contribute to dysregulated complement activation predisposing to SLE. We assessed 60 SNPs covering the CFH-CFHRs region for association with SLE in 15,864 case-control subjects derived from four ethnic groups. Significant allelic associations with SLE were detected in European Americans (EA) and African Americans (AA), which could be attributed to an intronic CFH SNP (rs6677604, in intron 11, P(meta)â=â6.6×10(-8), ORâ=â1.18) and an intergenic SNP between CFHR1 and CFHR4 (rs16840639, P(meta)â=â2.9×10(-7), ORâ=â1.17) rather than to previously identified disease-associated CFH exonic SNPs, including I62V, Y402H, A474A, and D936E. In addition, allelic association of rs6677604 with SLE was subsequently confirmed in Asians (AS). Haplotype analysis revealed that the underlying causal variant, tagged by rs6677604 and rs16840639, was localized to a ~146 kb block extending from intron 9 of CFH to downstream of CFHR1. Within this block, the deletion of CFHR3 and CFHR1 (CFHR3-1Δ), a likely causal variant measured using multiplex ligation-dependent probe amplification, was tagged by rs6677604 in EA and AS and rs16840639 in AA, respectively. Deduced from genotypic associations of tag SNPs in EA, AA, and AS, homozygous deletion of CFHR3-1Δ (P(meta)â=â3.2×10(-7), ORâ=â1.47) conferred a higher risk of SLE than heterozygous deletion (P(meta)â=â3.5×10(-4), ORâ=â1.14). These results suggested that the CFHR3-1Δ deletion within the SLE-associated block, but not the previously described exonic SNPs of CFH, might contribute to the development of SLE in EA, AA, and AS, providing new insights into the role of complement regulators in the pathogenesis of SLE.
Subject(s)
Antigens, Neoplasm/genetics , Biomarkers, Tumor/genetics , Complement Factor H/genetics , Genetic Predisposition to Disease , Lupus Erythematosus, Systemic/genetics , Polymorphism, Single Nucleotide , Black or African American/genetics , Alleles , Asian People/genetics , Case-Control Studies , Chromosomes, Human, Pair 1/genetics , Gene Deletion , Gene Frequency , Genotype , Hispanic or Latino/genetics , Humans , Introns , Lupus Erythematosus, Systemic/ethnology , White People/geneticsABSTRACT
A series of novel tri-2,3,5-substituted tetrahydropyran analogs were synthesized and evaluated as inhibitors of dipeptidyl peptidase IV (DPP-4) for the treatment of type 2 diabetes. Optimization of the series provided inhibitors with good DPP-4 potency and selectivity over other peptidases (QPP, DPP8, and FAP). Compound 23, which is very potent, selective, efficacious in the diabetes PD model, and has an excellent pharmacokinetic profile, is selected as a clinical candidate.
Subject(s)
Dipeptidyl-Peptidase IV Inhibitors/chemical synthesis , Heterocyclic Compounds, 2-Ring/chemical synthesis , Pyrans/chemical synthesis , Animals , Diabetes Mellitus, Type 2/drug therapy , Dipeptidyl-Peptidase IV Inhibitors/chemistry , Dipeptidyl-Peptidase IV Inhibitors/pharmacology , Dogs , Enzyme Activation/drug effects , Glucose Tolerance Test , Haplorhini , Humans , Inhibitory Concentration 50 , Pyrans/chemistry , Pyrans/pharmacology , Rats , StereoisomerismABSTRACT
Systemic lupus erythematosus (SLE) is a multisystem, autoimmune disease that predominantly affects women. Previous findings that duplicated Toll-like receptor 7 (Tlr7) promotes lupus-like disease in male BXSB mice prompted us to evaluate TLR7 in human SLE. By using a candidate gene approach, we identified and replicated association of a TLR7 3'UTR SNP, rs3853839 (G/C), with SLE in 9,274 Eastern Asians (P(combined) = 6.5 x 10(-10)), with a stronger effect in male than female subjects [odds ratio, male vs. female = 2.33 (95% CI = 1.64-3.30) vs. 1.24 (95% CI = 1.14-1.34); P = 4.1 x 10(-4)]. G-allele carriers had increased TLR7 transcripts and more pronounced IFN signature than C-allele carriers; heterozygotes had 2.7-fold higher transcripts of G-allele than C-allele. These data established a functional polymorphism in type I IFN pathway gene TLR7 predisposing to SLE, especially in Chinese and Japanese male subjects.
Subject(s)
Genetic Diseases, X-Linked/genetics , Lupus Erythematosus, Systemic/genetics , Sex Factors , Toll-Like Receptor 7/genetics , Alleles , Asian People , Genetic Predisposition to Disease , Humans , Male , Polymorphism, Single Nucleotide , RNA, Messenger/geneticsABSTRACT
Systemic lupus erythematosus is a complex and potentially fatal autoimmune disease, characterized by autoantibody production and multi-organ damage. By a genome-wide association study (320 patients and 1,500 controls) and subsequent replication altogether involving a total of 3,300 Asian SLE patients from Hong Kong, Mainland China, and Thailand, as well as 4,200 ethnically and geographically matched controls, genetic variants in ETS1 and WDFY4 were found to be associated with SLE (ETS1: rs1128334, P = 2.33x10(-11), OR = 1.29; WDFY4: rs7097397, P = 8.15x10(-12), OR = 1.30). ETS1 encodes for a transcription factor known to be involved in a wide range of immune functions, including Th17 cell development and terminal differentiation of B lymphocytes. SNP rs1128334 is located in the 3'-UTR of ETS1, and allelic expression analysis from peripheral blood mononuclear cells showed significantly lower expression level from the risk allele. WDFY4 is a conserved protein with unknown function, but is predominantly expressed in primary and secondary immune tissues, and rs7097397 in WDFY4 changes an arginine residue to glutamine (R1816Q) in this protein. Our study also confirmed association of the HLA locus, STAT4, TNFSF4, BLK, BANK1, IRF5, and TNFAIP3 with SLE in Asians. These new genetic findings may help us to gain a better understanding of the disease and the functions of the genes involved.
Subject(s)
Asian People/genetics , Genetic Predisposition to Disease , Genome-Wide Association Study , Intracellular Signaling Peptides and Proteins/genetics , Lupus Erythematosus, Systemic/genetics , Polymorphism, Single Nucleotide/genetics , Proto-Oncogene Protein c-ets-1/genetics , Adaptor Proteins, Signal Transducing/genetics , Adult , Alleles , Cohort Studies , DNA-Binding Proteins , Female , Haplotypes/genetics , Humans , Interferon Regulatory Factors/genetics , Leukocytes, Mononuclear/metabolism , Linkage Disequilibrium/genetics , Lupus Erythematosus, Systemic/enzymology , Male , Membrane Proteins/genetics , Nuclear Proteins/genetics , Principal Component Analysis , Reproducibility of Results , STAT4 Transcription Factor/genetics , Tumor Necrosis Factor alpha-Induced Protein 3 , src-Family Kinases/geneticsABSTRACT
OBJECTIVE: A previous genome-wide association study conducted in a population of European ancestry identified rs4963128, a KIAA1542 single-nucleotide polymorphism (SNP) 23 kb telomeric to IRF7 (the gene for interferon regulatory factor 7 [IRF-7]), to be strongly associated with systemic lupus erythematosus (SLE). This study was undertaken to investigate whether genetic polymorphism within IRF7 is a risk factor for the development of SLE. METHODS: We genotyped one KIAA1542 SNP (rs4963128) and one IRF7 SNP (rs1131665 [Q412R]) in an Asian population (1,302 cases, 1,479 controls), to assess their association with SLE. Subsequently, rs1131665 was further genotyped in independent panels of Chinese subjects (528 cases, 527 controls), European American subjects (446 cases, 461 controls), and African American subjects (159 cases, 115 controls) by TaqMan genotyping assay, to seek confirmation of association in various ethnic groups. A luciferase reporter assay was used to assess the effect of Q412R polymorphism on the activation of IRF-7. RESULTS: Consistent association of rs1131665 (Q412R) with SLE was identified in Asian, European American, and African American populations (total 2,435 cases and 2,582 controls) (P(meta) = 6.18 × 10(-6) , odds ratio 1.42 [95% confidence interval 1.22-1.65]). Expression of the IRF7 412Q risk allele resulted in a 2-fold increase in interferon-stimulated response element transcriptional activity compared with expression of IRF7 412R (P = 0.0003), suggesting that IRF7 412Q confers elevated IRF-7 activity and may therefore affect a downstream interferon pathway. CONCLUSION: These findings show that the major allele of a nonsynonymous SNP, rs1131665 (412Q) in IRF7, confers elevated activation of IRF-7 and predisposes to the development of SLE in multiple ethnic groups. This result provides direct genetic evidence that IRF7 may be a risk gene for human SLE.
Subject(s)
Ethnicity/genetics , Interferon Regulatory Factor-7/genetics , Lupus Erythematosus, Systemic/ethnology , Lupus Erythematosus, Systemic/genetics , Adult , Black or African American/genetics , Black or African American/statistics & numerical data , Amino Acid Sequence , Asian People/genetics , Asian People/statistics & numerical data , Ethnicity/statistics & numerical data , Female , Genetic Predisposition to Disease/epidemiology , Genetic Predisposition to Disease/genetics , Genetic Variation/genetics , Genome-Wide Association Study , Genotype , Humans , Interferon Regulatory Factor-7/immunology , Lupus Erythematosus, Systemic/immunology , Male , Molecular Sequence Data , Polymorphism, Single Nucleotide/genetics , Risk Factors , White People/genetics , White People/statistics & numerical dataABSTRACT
Background: When we treated the C.836A/G-caused short stature girls with rhGH (recombinant growth hormone) for short stature, the effect of height improvement was good, but in the course of treatment, there was a side effect of leukopenia, which led to the interruption of treatment. We consult the literature, did not find such relevant reports, therefore, the objective of this study is to share the novel treatment method of C.836A/G-caused short stature and report the treatment response and adverse events of the child with C.836A/G-caused short stature. Case Description: The clinical data of 1 child with C.836A/G-caused short stature were collected, and the efficacy of rhGH in the treatment of this child was observed. The female child aged 5 years and 5 months old was treated at our hospital for growth retardation of >5 years. The child was a slightly picky eater, had good sleep quality (she often fell asleep after 21:00), and did not exercise much before the age of 3-4 years. Routine blood results and other relevant indicators were also monitored during the treatment. The growth rate of the child was followed up over a period of 16 months using needle withdrawal, and routine blood examinations were conducted regularly. With the application of rhGH, the child with C.836A/G-caused short stature gained 9.6 cm in height at 11 months, and had a height of standard deviation score of -1.01. Throughout the treatment, the blood hemoglobin and platelets of the child were normal, but the content of the granulocytes was lower than the normal value. Some 16 months after the discontinuation of the rhGH therapy, the granulocytes gradually returned to the normal range, but the growth rate of the child declined obviously. Conclusions: Recombinant growth hormone treatment of this case of C.836A/G-caused short stature is effective, but in the course of treatment, we need to pay attention to the side effects of the hematological system. Due to our limited clinical experience with these cases, please correct us for any inaccuracies.
ABSTRACT
Protein conjugation is an effective way to impart different functionalities to the original protein. Conjugation using a native protein (a protein that does not contain special unnatural amino acid for conjugation) typically generates complex mixtures mainly due to the presence of multiple chemically similar competing conjugation sites. It is therefore a challenge to identify products, to optimize the reaction conditions, and to synthesize desired molecules. In order to guide this challenging process, quick and easy analytical methods are in great need for reaction monitoring. An analytical platform was developed for this purpose by using liquid chromatography/high resolution mass spectrometry (LC/HRMS) coupled with a custom-built software tool via Visual Basic for Applications in Excel (VBA). It allows for not only the determination of site-selective modification, but also the evaluation of the scope for possible modification sites. This vendor neutral VBA based software tool combined with enzymatic digestion, especially the SMART Digest™ method, and LC/HRMS would shorten the experimental time and data analysis from days to a few hours. Open-source VBA features a data fitting interface with the support for arbitrary functions and flexible global fits. Two conjugated proteins were used to demonstrate the capability of this VBA tool. Major conjugation sites are presented in a graphic format via its mass and ion intensity and chemists can visually estimate the ratio of modified vs unmodified proteins.
Subject(s)
Proteins , Software , Chromatography, Liquid , Mass SpectrometryABSTRACT
OBJECTIVES: Recently, a non-synonymous (Gly307Ser) variant, rs763361, in the CD226 gene was shown to be associated with multiple autoimmune diseases (ADs) in European Caucasian populations. However, shared autoimmunity with CD226 has not been evaluated in non-European populations. The aim of the present study is to assess the association of this single nucleotide polymorphism (SNP) with ADs in non-European populations. METHODS: To replicate this association in non-European populations, we evaluated case-control association between rs763361 and coeliac disease (CED) samples from Argentina; SLE, RA, type-1 diabetes (T1D) and primary SS (pSS) from Colombia; and SLE samples from China and Japan. We genotyped rs763361 and evaluated its genetic association with multiple ADs, using chi(2)-test. For each association, odds ratio (OR) and 95% CI were calculated. RESULTS: We show that rs763361 is significantly associated with Argentinean CED (P = 0.0009, OR = 1.60). We also observed a trend of possible association with Chinese SLE (P = 0.01, OR = 1.19), RA (P = 0.047, OR = 1.25), SLE (P = 0.0899, OR = 1.24) and pSS (P = 0.09, OR = 1.33) in Colombians. Meta-analyses for SLE (using our three populations) and T1D (our population and three published populations) yielded significant association with rs763361, P = 0.009 (OR = 1.16) and P = 1.1.46 x 10(-9) (OR = 1.14), respectively. CONCLUSIONS: Our results demonstrate that the coding variant rs763361 in CD226 gene is associated with multiple ADs in non-European populations.
Subject(s)
Antigens, Differentiation, T-Lymphocyte/genetics , Autoimmune Diseases/genetics , Genetic Predisposition to Disease/genetics , Argentina , Asian People/genetics , Case-Control Studies , Colombia , Gene Frequency , Genotype , Humans , Statistics as Topic , White People/geneticsABSTRACT
Probing with tool molecules, and by modeling and X-ray crystallography the binding modes of two structurally distinct series of DPP-4 inhibitors led to the discovery of a rare aromatic fluorine H-bond and the spatial requirement for better biaryl binding in the DPP-4 enzyme active site. These newly found binding elements were successfully incorporated into novel DPP-4 inhibitors.
Subject(s)
Dipeptidyl Peptidase 4/chemistry , Binding Sites , Chemistry, Pharmaceutical/methods , Crystallography, X-Ray/methods , Dipeptidyl-Peptidase IV Inhibitors , Drug Design , Fluorine/chemistry , Glycine/chemistry , Humans , Hydrogen Bonding , Inhibitory Concentration 50 , Models, Chemical , Models, Theoretical , Molecular Conformation , Software , beta-Alanine/chemistryABSTRACT
Diaryl-(4-piperidinyl)-pyrrole derivatives bearing cyclic amine substituents have been synthesized and evaluated as anticoccidial agents. Improvements in potency of Et-PKG inhibition, such as azetidine derivative 3a, and broad spectrum anticoccidial activities in feed, such as morpholine derivative 8c, have been achieved.
Subject(s)
Coccidiosis/drug therapy , Coccidiostats/pharmacology , Eimeria/drug effects , Pyrroles/pharmacology , Animals , Chickens , Coccidiostats/chemical synthesis , Cyclic GMP-Dependent Protein Kinases/antagonists & inhibitors , Eimeria/enzymology , Female , Molecular Structure , Oocysts/drug effects , Oocysts/physiology , Protein Kinase Inhibitors/pharmacology , Pyrroles/chemical synthesis , Pyrroles/chemistry , Structure-Activity RelationshipABSTRACT
Dipeptidyl peptidase (DPP)-IV inhibitors are a new approach to the treatment of type 2 diabetes. DPP-IV is a member of a family of serine peptidases that includes quiescent cell proline dipeptidase (QPP), DPP8, and DPP9; DPP-IV is a key regulator of incretin hormones, but the functions of other family members are unknown. To determine the importance of selective DPP-IV inhibition for the treatment of diabetes, we tested selective inhibitors of DPP-IV, DPP8/DPP9, or QPP in 2-week rat toxicity studies and in acute dog tolerability studies. In rats, the DPP8/9 inhibitor produced alopecia, thrombocytopenia, reticulocytopenia, enlarged spleen, multiorgan histopathological changes, and mortality. In dogs, the DPP8/9 inhibitor produced gastrointestinal toxicity. The QPP inhibitor produced reticulocytopenia in rats only, and no toxicities were noted in either species for the selective DPP-IV inhibitor. The DPP8/9 inhibitor was also shown to attenuate T-cell activation in human in vitro models; a selective DPP-IV inhibitor was inactive in these assays. Moreover, we found DPP-IV inhibitors that were previously reported to be active in models of immune function to be more potent inhibitors of DPP8/9. These results suggest that assessment of selectivity of potential clinical candidates may be important to an optimal safety profile for this new class of antihyperglycemic agents.
Subject(s)
Diabetes Mellitus, Type 2/drug therapy , Dipeptidases/antagonists & inhibitors , Dipeptidyl Peptidase 4 , Dipeptidyl-Peptidases and Tripeptidyl-Peptidases/antagonists & inhibitors , Hypoglycemic Agents , Protease Inhibitors/therapeutic use , Animals , Dipeptidyl Peptidase 4/genetics , Dipeptidyl Peptidase 4/physiology , Dogs , Female , Humans , Hypoglycemic Agents/therapeutic use , Hypoglycemic Agents/toxicity , Isoleucine/analogs & derivatives , Isoleucine/chemistry , Isoleucine/therapeutic use , Isoleucine/toxicity , Isomerism , Male , Mice , Mice, Inbred C57BL , Mice, Knockout , Protease Inhibitors/toxicity , Rats , Recombinant Proteins/antagonists & inhibitors , Thiazoles/chemistry , Thiazoles/therapeutic use , Thiazoles/toxicityABSTRACT
In our effort to discover DPP-4 inhibitors with added benefits over currently commercially available DPP-4 inhibitors, MK-3102 (omarigliptin), was identified as a potent and selective dipeptidyl peptidase 4 (DPP-4) inhibitor with an excellent pharmacokinetic profile amenable for once-weekly human dosing and selected as a clinical development candidate. This manuscript summarizes the mechanism of action, scientific rationale, medicinal chemistry, pharmacokinetic properties, and human efficacy data for omarigliptin, which is currently in phase 3 clinical development.
Subject(s)
Diabetes Mellitus, Type 2/drug therapy , Dipeptidyl-Peptidase IV Inhibitors/pharmacology , Heterocyclic Compounds, 2-Ring/pharmacology , Hypoglycemic Agents/pharmacology , Pyrans/pharmacology , Animals , Dipeptidyl-Peptidase IV Inhibitors/chemical synthesis , Dipeptidyl-Peptidase IV Inhibitors/pharmacokinetics , Dipeptidyl-Peptidase IV Inhibitors/toxicity , Heterocyclic Compounds, 2-Ring/chemical synthesis , Heterocyclic Compounds, 2-Ring/pharmacokinetics , Heterocyclic Compounds, 2-Ring/toxicity , Humans , Hypoglycemic Agents/chemical synthesis , Hypoglycemic Agents/pharmacokinetics , Hypoglycemic Agents/toxicity , Pyrans/chemical synthesis , Pyrans/pharmacokinetics , Pyrans/toxicity , Structure-Activity RelationshipABSTRACT
AIM: It has long been a controversy that polymorphisms in FcγRIIIa (CD16A) receptors are associated with systemic lupus erythematosus (SLE). We aimed to verify the association of FcγRIIIa polymorphisms with SLE in a large Chinese population. METHODS: We genotyped FcγRIIIa-158V/F (rs396991) using a pyro-sequencing assay (PSQ 96MA) in a total of 732 individuals with SLE (390 lupus nephritis and 342 non-lupus nephritis) and 886 controls. Meta-analysis was used to examine the association of the FcγRIIIa-F158 allele with SLE and lupus nephritis with RevMan 5. RESULTS: The allele frequencies of FcγRIIIa-F158 were significantly increased in SLE (OR 1.293, 95%CI 1.111-1.505, P = 0.0009). There was significant skewing in the distribution of FcγRIIIa genotypes between SLE patients and controls (P = 0.0026 for 158 F/F vs. 158F/V and 158V/V, OR 1.604, 95%CI 1.089-2.361). Serositis was more common in patients with the FcγRIIIa-F158 allele and FcγRIIIa-F/F genotype, and low complement was more common in patients with the FcγRIIIa-F/F genotype. There was no skewing in the distribution of FcγRIIIa genotypes in the lupus nephritis group. No association was found for the frequencies of the FcγRIIIa-F158 allele and 158F/F genotype compared with the V158 allele and F/V plus V/V genotypes, respectively, between lupus nephritis and SLE without nephritis patients in a meta-analysis of 11 Asian studies. CONCLUSION: Our results suggest that the low-binding allele FcγRIIIa-158F is one of the risk factors for SLE in the Chinese population.
Subject(s)
Lupus Erythematosus, Systemic/genetics , Polymorphism, Genetic , Receptors, IgG/genetics , Adolescent , Adult , Asian People/genetics , Case-Control Studies , Chi-Square Distribution , China/epidemiology , Female , Gene Frequency , Genetic Predisposition to Disease , Humans , Lupus Erythematosus, Systemic/ethnology , Lupus Erythematosus, Systemic/immunology , Lupus Nephritis/ethnology , Lupus Nephritis/genetics , Lupus Nephritis/immunology , Male , Odds Ratio , Phenotype , Risk Factors , Young AdultABSTRACT
Diaryl imidazo[1,2-a]pyridine derivatives, such as 6a and 7i, have been synthesized and found to be potent inhibitors of parasite PKG activity. The most potent compounds are the 7-isopropylaminomethyl analog 6a and 2-isopropylamino analog 7i. These compounds are also fully active in in vivo assay as anticoccidial agents at 25 ppm in feed.
Subject(s)
Coccidiosis/drug therapy , Coccidiostats/pharmacology , Imidazoles/chemistry , Protein Kinase Inhibitors/pharmacology , Pyridines/chemistry , Pyridines/pharmacology , Animals , Chemistry, Pharmaceutical/methods , Coccidiostats/chemistry , Cyclic GMP-Dependent Protein Kinases/metabolism , Drug Design , Eimeria tenella , Models, Chemical , Protein Kinase Inhibitors/chemistry , Structure-Activity RelationshipABSTRACT
Following the discovery of N-acyl-1,4-diazepan-2-one as a novel pharmacophore for potent and selective DPP-4 inhibitors, optimization of this new lead with different substitution on the seven-membered ring resulted in several highly potent and selective, orally bioavailable, and efficacious DPP-4 inhibitors, such as 3R-methyl-1-cyclopropyl-1,4-diazepan-2-one derivative 9i (DPP-4 IC(50)=8.0 nM) and 3R,6R-dimethyl-1,4-diazepan-2-one derivative 14a (DPP-4 IC(50)=9.7 nM).
Subject(s)
Azepines/chemical synthesis , Chemistry, Pharmaceutical/methods , Diabetes Mellitus, Type 2/drug therapy , Dipeptidyl-Peptidase IV Inhibitors , Enzyme Inhibitors/chemical synthesis , Enzyme Inhibitors/pharmacology , Administration, Oral , Animals , Azepines/pharmacology , Drug Design , Inhibitory Concentration 50 , Male , Mice , Models, Chemical , Molecular Conformation , Rats , Rats, Sprague-DawleyABSTRACT
Replacement of the triazolopiperazine ring of sitagliptin (DPP-4 IC(50)=18nM) with 3-(2,2,2-trifluoroethyl)-1,4-diazepan-2-one gave dipeptidyl peptidase IV (DPP-4) inhibitor 1 which is potent (DPP-4 IC(50)=2.6nM), selective, and efficacious in an oral glucose tolerance test in mice. It was selected for extensive preclinical development as a potential back-up candidate to sitagliptin.